| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -NOK 42.2M | ROE | −13.86% |
| Net Margin | — | ROIC | −15.64% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Thor Medical ASA produces and supplies alpha-particle emitters used in cancer therapy. Based in Oslo, Norway, the company sells thorium-228 along with radium-224 and lead-212 to radiopharmaceutical customers. It was incorporated in 2009.
| Market Cap | $52.2M | Trading Days | 2803 |
| 52W High | 5.73 |
| 52W Low | 2.37 |
| % Off High | −22.51% |
| YTD | −15.43% | 1Y | 79.39% |
| 3Y | 146.39% | 5Y | −79.10% |
| 10Y | −81.76% | Since incept. (ann.) | −16.51% |
| Ann. Volatility (1Y) | 58.61% | Ann. Volatility (3Y) | 86.76% |
| Sharpe (1Y) | 1.32 | Sharpe (3Y) | 0.79 |
| Max Drawdown (1Y) | −30.05% | Max Drawdown (3Y) | −54.04% |
| Beta (3Y, vs SPY) | 1.55 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| DWTX | Dogwood Therapeutics, Inc. | $52.1M | — |
| COCH | Envoy Medical, Inc. | $52.2M | — |
| INKT | MiNK Therapeutics, Inc. | $52.5M | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
| LUNG | Pulmonx Corp | $52.8M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M | — |
| MRAI | Marpai, Inc. | $53.1M | — |
| APT | ALPHA PRO TECH LTD | $51.1M | 15.2 |
| ECOR | electroCore, Inc. | $50.5M | — |
| CTOR | CITIUS ONCOLOGY, INC. | $50.3M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
